Karen A. Dawes Sells 1,295 Shares of Repligen Co. (NASDAQ:RGEN) Stock

Share on StockTwits

Repligen Co. (NASDAQ:RGEN) Director Karen A. Dawes sold 1,295 shares of the stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $77.35, for a total transaction of $100,168.25. Following the completion of the sale, the director now directly owns 118,329 shares in the company, valued at $9,152,748.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

RGEN traded up $2.05 on Wednesday, reaching $81.10. The company had a trading volume of 816,300 shares, compared to its average volume of 373,603. The company has a market capitalization of $3.66 billion, a P/E ratio of 111.10, a P/E/G ratio of 4.78 and a beta of 1.00. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.18 and a quick ratio of 1.84. Repligen Co. has a 52-week low of $45.00 and a 52-week high of $81.31.

Repligen (NASDAQ:RGEN) last announced its earnings results on Thursday, May 9th. The biotechnology company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.02. The business had revenue of $60.63 million for the quarter, compared to the consensus estimate of $55.09 million. Repligen had a net margin of 10.11% and a return on equity of 6.35%. Repligen’s quarterly revenue was up 35.3% on a year-over-year basis. During the same period last year, the firm posted $0.17 earnings per share. On average, equities analysts anticipate that Repligen Co. will post 0.93 earnings per share for the current year.

RGEN has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Repligen from a “sell” rating to a “hold” rating in a report on Wednesday, February 27th. BidaskClub downgraded shares of Repligen from a “hold” rating to a “sell” rating in a report on Tuesday, April 9th. Finally, ValuEngine downgraded shares of Repligen from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 4th. Three analysts have rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $64.20.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Westpac Banking Corp boosted its holdings in Repligen by 9.3% in the first quarter. Westpac Banking Corp now owns 94,885 shares of the biotechnology company’s stock valued at $5,606,000 after acquiring an additional 8,100 shares in the last quarter. American Capital Management Inc. boosted its holdings in Repligen by 3.8% in the first quarter. American Capital Management Inc. now owns 73,340 shares of the biotechnology company’s stock valued at $4,333,000 after acquiring an additional 2,665 shares in the last quarter. OppenheimerFunds Inc. boosted its holdings in Repligen by 9.0% in the first quarter. OppenheimerFunds Inc. now owns 1,082,943 shares of the biotechnology company’s stock valued at $63,980,000 after acquiring an additional 89,226 shares in the last quarter. Yorktown Management & Research Co Inc bought a new stake in Repligen in the first quarter valued at $448,000. Finally, Federated Investors Inc. PA lifted its position in Repligen by 0.9% during the first quarter. Federated Investors Inc. PA now owns 950,414 shares of the biotechnology company’s stock valued at $56,150,000 after buying an additional 8,641 shares during the period. 84.90% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This story was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/4380018/karen-a-dawes-sells-1295-shares-of-repligen-co-nasdaqrgen-stock.html.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

See Also: Why do companies issue stock splits?

Insider Buying and Selling by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

MKM Partners Lowers ADTRAN  Price Target to $17.00
MKM Partners Lowers ADTRAN Price Target to $17.00
Apple  PT Raised to $180.00 at Nomura
Apple PT Raised to $180.00 at Nomura
Advaxis  Lowered to “Hold” at ValuEngine
Advaxis Lowered to “Hold” at ValuEngine
Zacks Investment Research Upgrades Atlas Air Worldwide  to “Hold”
Zacks Investment Research Upgrades Atlas Air Worldwide to “Hold”
Apple  Raised to “Outperform” at Raymond James
Apple Raised to “Outperform” at Raymond James
Zacks Investment Research Lowers Agilysys  to Hold
Zacks Investment Research Lowers Agilysys to Hold


© 2006-2019 Ticker Report